Xenon Pharmaceuticals (XENE) reported a Q3 net loss late Tuesday of $0.81 per diluted share, widening from the loss of $0.73 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.81.

No revenue was recorded in the three months ended Sept. 30, as expected.

The company had $803.3 million in cash and cash equivalents and marketable securities at the end of September and expects to have sufficient cash to fund operations into 2027.